Provided by Tiger Fintech (Singapore) Pte. Ltd.

SELLAS Life Sciences Group Inc.

1.21
+0.0000
Post-market: 1.13-0.0800-6.61%19:59 EDT
Volume:634.20K
Turnover:762.66K
Market Cap:95.08M
PE:-1.89
High:1.23
Open:1.20
Low:1.18
Close:1.21
Loading ...

Sellas Life Sciences Group: Idmc Has Recommended That Trial Continue Without Modifications

THOMSON REUTERS
·
23 Jan

Sellas Life Sciences Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia

THOMSON REUTERS
·
23 Jan

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

GlobeNewswire
·
23 Jan

BRIEF-Sellas Life Sciences Says Full Topline Phase 2 Data In Acute Myeloid Leukemia And FDA Regulatory Review Expected In 1H 2025 For SLS009

Reuters
·
08 Jan

Sellas Life Sciences Group Inc: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 for Sls009

THOMSON REUTERS
·
08 Jan

SELLAS Announces Key Business Objectives for 2025

GlobeNewswire
·
08 Jan

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

GlobeNewswire
·
02 Jan

Prediction: NASA's Big Moon Mission Hiccup Will Cost Boeing Another $4 Billion in 2025

Motley Fool
·
15 Dec 2024

Sellas Life Sciences Triggers Interim Analysis in Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia

THOMSON REUTERS
·
10 Dec 2024

Sellas Life Sciences Group: Regal Independent Data Monitoring Committee to Perform Interim Analysis in Jan 2025

THOMSON REUTERS
·
10 Dec 2024

Sellas Life Sciences Group: Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating Interim Analysis

THOMSON REUTERS
·
10 Dec 2024

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

GlobeNewswire
·
10 Dec 2024

Sellas Life Sciences Group Inc - Sls009 Well-Tolerated With No New Safety Signals Observed

THOMSON REUTERS
·
09 Dec 2024

Sellas Announces Positive Overall Survival and Overall Response Rate Data From the Phase 2 Trial of Sls009 in R/R Aml

THOMSON REUTERS
·
09 Dec 2024

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

GlobeNewswire
·
09 Dec 2024

BUZZ-Sellas rises on preclinical data for blood cancer drug

Reuters
·
27 Nov 2024